The company is developing nuclear medicine-based theranostics technologies that combine both treatment and diagnosis in cancer therapy.
It is also promoting the domestic introduction of ^68Ga-based PET radiopharmaceuticals that are already available in Europe and the United States.
These efforts contribute to expanding access to a wide range of nuclear medicine therapies for patients in need.

JURO SCIENCE Inc. is conducting research and development of SFG-02, a preclinical candidate for the treatment of underactive bladder (UAB), a condition characterised by impaired bladder voiding function and residual urine due to ageing or central and peripheral nervous system disorders.

They have in-licensed SFG-002, a compound that had progressed to a Phase IIa clinical trial at Takeda Pharmaceutical Company, and are developing it as a novel therapeutic agent for UAB with a new formulation and clinical development strategy.

We offer early disease diagnosis services based on gene expression analysis technology primarily using RNA derived from blood.
Our main services include the manufacture and sale of the pancreatic cancer test kit “PanRegza® (Approval Number 30400EZX00046000)” and contract analysis services.

The company is engaged in research and development aimed at advancing mobility technologies, and is involved in the manufacturing and sales of products related to advanced mobility systems.

The company is engaged in the research, development, manufacturing, and sales of porous materials. It also provides contract analysis and consulting services using porous materials for molecular structure determination, as well as the design, development, and sales of analytical instruments and software for molecular structure analysis.
In the field of crystalline materials, such as metal–organic frameworks (MOFs), the company offers a wide range of services, including molecular structure analysis, sales, custom development, and technical consulting.

A medical venture focused on developing program-based medical devices using uniquely analyzed vital data.
Currently developing a diabetes treatment app called “glucose flight,” which features AI-powered automatic blood glucose level prediction for patients with type 2 diabetes.
Our mission is to “design next-generation treatments with digital therapeutics.”